Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-05-14 Major Shareholding Noti…
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 12, 2025. It details an underwriting agreement for a stock offering, including the number of shares, price, net proceeds, and use of proceeds. The document includes legal opinions and exhibits related to the offering. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The content focuses on a capital raising event and related agreements. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing event, not just an announcement or certification, supporting a high confidence classification.
2025-05-13 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering terms, underwriting, use of proceeds, risk factors, and company overview. It is not a financial report, earnings release, or management discussion, but rather a capital raising document describing the issuance of new shares. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length and content confirm it is not merely an announcement but the actual offering prospectus supplement.
2025-05-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2025, reporting unaudited financial results for the quarter ended March 31, 2025. It includes a press release with first quarter 2025 financial results and a business update. The document explicitly states it is a current report and includes financial highlights but does not contain full financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory filing to announce earnings results and other business updates. The document length is about 10,305 characters, which is consistent with a detailed 8-K but not a full quarterly report. The presence of a press release and the nature of the content align with an Earnings Release (ER) filing rather than a full Interim Report (IR) or Annual Report (10-K). Therefore, the best classification is Earnings Release (ER).
2025-05-12 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-12 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (1139 characters) and does not contain financial statements or detailed financial data, but rather is related to shareholder voting information. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2025-04-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.